Translate

The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

About Us
Interviews

What does real-world data tell us about frontline therapy with CPX-351 vs Ven + Aza?

Alexander E. Perl

January 21, 2022

During the 63rd ASH Annual Meeting and Exposition, Know AML spoke with Alexander E. Perl, University of Pennsylvania, Philadelphia, US. We asked, What does real-world data tell us about frontline therapy with CPX-351 versus venetoclax + azacitidine?

Perl begins by discussing recent data on CPX-351 in older patients and available regimens for clinicians to choose from. He goes on to outline the importance of analyzing real-world data, and highlights some studies presented at ASH. Perl explains his study, and remarks that there was no significant difference in overall survival (OS) between the two treatments; however, there were differences in comorbidities and toxicities.